GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enimmune Corp (ROCO:6564) » Definitions » EV-to-Revenue

Enimmune (ROCO:6564) EV-to-Revenue : 20.94 (As of Jun. 24, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Enimmune EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Enimmune's enterprise value is NT$835.77 Mil. Enimmune's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$39.92 Mil. Therefore, Enimmune's EV-to-Revenue for today is 20.94.

The historical rank and industry rank for Enimmune's EV-to-Revenue or its related term are showing as below:

ROCO:6564' s EV-to-Revenue Range Over the Past 10 Years
Min: 10.4   Med: 52.47   Max: 1413.04
Current: 20.94

During the past 9 years, the highest EV-to-Revenue of Enimmune was 1413.04. The lowest was 10.40. And the median was 52.47.

ROCO:6564's EV-to-Revenue is ranked worse than
70.35% of 995 companies
in the Biotechnology industry
Industry Median: 7.6 vs ROCO:6564: 20.94

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-24), Enimmune's stock price is NT$15.65. Enimmune's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.56. Therefore, Enimmune's PS Ratio for today is 27.95.


Enimmune EV-to-Revenue Historical Data

The historical data trend for Enimmune's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enimmune EV-to-Revenue Chart

Enimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 98.24 18.25 19.47 51.57 38.62

Enimmune Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.47 - 51.57 - 38.62

Competitive Comparison of Enimmune's EV-to-Revenue

For the Biotechnology subindustry, Enimmune's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enimmune's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enimmune's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Enimmune's EV-to-Revenue falls into.


;
;

Enimmune EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Enimmune's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=835.772/39.915
=20.94

Enimmune's current Enterprise Value is NT$835.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Enimmune's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$39.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enimmune  (ROCO:6564) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Enimmune's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.65/0.56
=27.95

Enimmune's share price for today is NT$15.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.56.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enimmune EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Enimmune's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Enimmune Business Description

Traded in Other Exchanges
N/A
Address
Dunhua South Road, 18th Floor-2, No. 76, Section 2, Da’an District, Taipei, TWN, 10683
Enimmune Corp is primarily engaged in the research and development and trading of vaccines, testing reagents and biotechnology services, etc., as well as trading of related western medicines.

Enimmune Headlines

No Headlines